
doi: 10.1136/bmj.e4970
pmid: 22826593
Although the BMJ and Lancet provided Handel and colleagues access to information on reprint sales,1 the big US journals were unwilling to share this information. Our experience was similar when we investigated reprint sales.2 Much of the previous evidence in this field has been anecdotal, such as the infamous VIGOR trial of rofecoxib, where …
Drug Industry, Research Design, Research Support as Topic, Humans, Periodicals as Topic
Drug Industry, Research Design, Research Support as Topic, Humans, Periodicals as Topic
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 1 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
